HCW Biologics Inc. (NASDAQ:HCWB) Director Gary M. Winer Acquires 2,308 Shares

HCW Biologics Inc. (NASDAQ:HCWB) Director Gary M. Winer bought 2,308 shares of HCW Biologics stock in a transaction on Thursday, May 8th. The shares were acquired at an average price of $26.00 per share, for a total transaction of $60,008.00. Following the completion of the acquisition, the director now owns 2,733 shares in the company, valued at $71,058. This represents a 543.06% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

HCW Biologics Trading Down 20.0%

HCW Biologics stock opened at $5.72 on Monday. The firm has a market capitalization of $6.42 million, a P/E ratio of -5.72 and a beta of 0.85. HCW Biologics Inc. has a twelve month low of $5.22 and a twelve month high of $100.80. The stock’s fifty day simple moving average is $10.01 and its 200-day simple moving average is $14.75.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings results on Friday, March 28th. The company reported ($3.20) earnings per share (EPS) for the quarter. The company had revenue of $0.40 million during the quarter. HCW Biologics had a negative net margin of 1,067.82% and a negative return on equity of 2,516.84%.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.